{"id":1017428,"date":"2026-11-05T06:35:19","date_gmt":"2026-11-05T11:35:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/"},"modified":"2026-11-05T06:35:19","modified_gmt":"2026-11-05T11:35:19","slug":"evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/","title":{"rendered":"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET<\/b><\/p>\n<p class=\"bwalignc\"><i>Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader<\/i><\/p>\n<p>PALO ALTO, Calif. &amp; NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nEvommune, Inc. (NYSE: EVMN) (\u201cEvommune\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today.<\/p>\n<p>\nOn the webcast, President and Chief Executive Officer Luis Pe\u00f1a and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular glue degrader. Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed molecular glue degrader (MGD). Management will cover the biology of VAV1, EVO570\u2019s preclinical profile, the planned development path in rheumatoid arthritis, the terms of the transaction and how EVO570 fits within the Company\u2019s broader immunology pipeline.<\/p>\n<p><b>Webcast Information<\/b><\/p>\n<p>\nThe webcast will be available at 8:30 a.m. ET on Thursday, November 5, 2026, on the News &amp; Events page of the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.evommune.com%2Fnews-events%2Fir-calendar&amp;esheet=54635695&amp;newsitemid=20261105854292&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.evommune.com%2Fnews-events%2Fir-calendar&amp;index=1&amp;md5=7feab862d8075218eed11a85b2919bc6\">https:\/\/ir.evommune.com\/news-events\/ir-calendar<\/a>. An archived replay will remain on the website for 30 days following the event. The webcast will not include a live question-and-answer session; questions can be sent to the investor relations team.<\/p>\n<p><b>About EVO570<\/b><\/p>\n<p>\nEVO570 is an investigational, orally administered molecular glue degrader that directs VAV1 to the cell\u2019s protein-disposal machinery for degradation. VAV1 expression is largely restricted to immune cells, where it acts as a key signaling protein downstream of both the T-cell and B-cell receptors. EVO570 is an investigational drug candidate and has not been approved by any regulatory authority.<\/p>\n<p><b>About Evommune<\/b><\/p>\n<p>\nEvommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company\u2019s mission is to improve patients\u2019 daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.evommune.com&amp;esheet=54635695&amp;newsitemid=20261105854292&amp;lan=en-US&amp;anchor=www.evommune.com&amp;index=2&amp;md5=233b29d8b1073446228a9ddb3b6bf767\">www.evommune.com<\/a> and follow us on LinkedIn.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential therapeutic benefits of EVO570, the planned development path of EVO570, and the continued development of the Company\u2019s product candidates. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described under \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K filed with the SEC on March 5, 2026, as supplemented by its Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026, and its other SEC filings. The Company disclaims any obligation to update these statements, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261105854292\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261105854292\/en\/<\/a><\/span><\/p>\n<p>\nMedia and Investors:<br \/>\n<br \/>Megan Humphreys<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:megan.humphreys@evommune.com\">megan.humphreys@evommune.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Genetics Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261105854292\/en\/2715266\/3\/evommune.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader PALO ALTO, Calif. &amp; NEW YORK&#8211;(BUSINESS WIRE)&#8211; Evommune, Inc. (NYSE: EVMN) (\u201cEvommune\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today. On the webcast, President and Chief Executive Officer Luis Pe\u00f1a and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular glue degrader. Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017428","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader PALO ALTO, Calif. &amp; NEW YORK&#8211;(BUSINESS WIRE)&#8211; Evommune, Inc. (NYSE: EVMN) (\u201cEvommune\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today. On the webcast, President and Chief Executive Officer Luis Pe\u00f1a and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular glue degrader. Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights &hellip; Continue reading &quot;Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T11:35:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET\",\"datePublished\":\"2026-11-05T11:35:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/\"},\"wordCount\":560,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/\",\"name\":\"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-05T11:35:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/","og_locale":"en_US","og_type":"article","og_title":"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET - Market Newsdesk","og_description":"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader PALO ALTO, Calif. &amp; NEW YORK&#8211;(BUSINESS WIRE)&#8211; Evommune, Inc. (NYSE: EVMN) (\u201cEvommune\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today. On the webcast, President and Chief Executive Officer Luis Pe\u00f1a and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular glue degrader. Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights &hellip; Continue reading \"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T11:35:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET","datePublished":"2026-11-05T11:35:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/"},"wordCount":560,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/","name":"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-05T11:35:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105854292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evommune-announces-webcast-discussing-evo570-and-its-expanding-immunology-portfolio-today-at-830-a-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017428"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017428\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}